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This review discussed the contribution of eosinophilic upper airway inﬂammation includes allergic
rhinitis (AR) and chronic rhinosinusitis (CRS) to the pathophysiology and course of asthma, the repre-
sentative counterpart in the lower airway. The presence of concomitant AR can affect the severity of
asthma in patients who have both diseases; however, it is still debatable whether the presence of asthma
affects the severity of AR. Hypersensitivity, obstruction and/or inﬂammation in the lower airway can be
detected in patients with AR without awareness or diagnosis of asthma, and AR is known as a risk factor
for the new onset of wheeze and asthma both in children and adults. Allergen immunotherapy, phar-
macotherapy and surgery for AR can contribute to asthma control; however, a clear preventive effect on
the new onset of asthma has been demonstrated only for immunotherapy. Pathological similarities such
as epithelial shedding are also seen between asthma and CRS, especially eosinophilic CRS. Abnormal
sinus ﬁndings on computed tomography are seen in the majority of asthmatic patients, and asthmatic
patients with CRS show a signiﬁcant impairment in Quality of Life (QOL) and pulmonary function as
compared to those without CRS. Conversely, lower airway inﬂammation and dysfunction are seen in non-
asthmatic patients with CRS. Treatments for CRS that include pharmacotherapy such as anti-
leukotrienes, surgery, and aspirin desensitization show a beneﬁcial effect on concomitant asthma.
Acting as a gatekeeper of the united airways, the control of inﬂammation in the nose is crucial for
improvement of the QOL of patients with co-existing AR/CRS and asthma.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Upper airway inﬂammation includes otitis media, rhinitis, rhi-
nosinusitis, tonsillitis, and pharyngo-laryngitis. Due to the spread
of guidelines and the development of new treatments, most of
these diseases can be controlled bymedical interventions includinglogy e Head & Neck Surgery,
entistry and Pharmaceutical
.
kano).
ety of Allergology.
rgology. Production and hosting by Elspatient education, pharmacotherapy, immunotherapy and surgery.
On the other hand, some of these diseases are refractory to treat-
ments and lead to a long-lasting impairment of the quality of life
(QOL), the so called “severe chronic upper airway diseases”
(SCUADs).1 SCUADs include uncontrolled allergic rhinitis, eosino-
philic rhinosinusitis, aspirin exacerbated respiratory disease, ciliary
dyskinesia and cystic ﬁbrosis. Comorbid lower airway inﬂamma-
tion such as bronchitis and asthma is often seen in SCUADs. In this
review, we focus on two major eosinophilic inﬂammatory diseases
in the upper airway, allergic rhinitis (AR) and chronic rhinosinusitis
(CRS), and discuss their contribution to the pathophysiology of
asthma, the representative counterpart in the lower airway.evier B.V. All rights reserved.
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Pathological similarities and differences between AR and asthma
Upper and lower airways share common structures including
ciliary epithelium, basement membrane, lamina propria, glands
and goblet cells, the so called “United airways”.2 Thus AR and
asthma share pathological characteristics including the involve-
ment of Th2-type cytokines such as IL-5, IL-13 and IL-31, eosino-
philia-associated chemokines such as eotaxins, and cystenyl
leukotrienes, which lead to pathological changes such as thickness
of the basement membrane and goblet cell hyperplasia3e6 (Fig. 1).
For example, we have shown that peripheral blood mononuclear
cells (PBMCs) of two thirds of the patients with Japanese cedar/
cypress pollinosis (JCCP) produced a substantial amount of IL-31 in
response to pollen allergens, which was associated with the
severity of the disease (Fig. 2).3 In addition, we also found that IL-31
induces MUC5AC gene expression in human airway epithelial
cells.4 Furthermore, IL-31 was reported as a potential indicator in
patients with allergic asthma; for example, IL-31 signiﬁcantly
induced vascular epithelial growth factor in human bronchial
epithelial cells.5
On the other hand, differences between the upper and lower
airways do exist. Thus, nasal mucosa attaches to bone whereas
bronchial mucosa attaches to cartilage. Nasal mucosa is enriched
with vessels whereas bronchial mucosa is enriched with smooth
muscle cells. Thus the major cause of airway obstruction, especially
in the early phase of the allergic response, is different; upper airway
obstruction is caused by vascular dilation whereas lower airway
obstruction arises from smooth muscle constriction (Fig. 2). In
terms of remodeling, epithelial shedding is frequently seen in
asthmatic bronchi but not in the nose of patients with AR.Presence and characterization of comorbidity of allergic rhinitis and
asthma
It is well-known that AR and asthma co-exist. In general, asthma
occurs in 10e40% of patients with ARwhereas AR occurs in 20e80%Fig. 1. Pathological similarities and differences betweeof patients with asthma.7e13 Variation in the percentage with co-
morbidity may arise from differences in diagnostic criteria (e.g.
questionnaire differences) and/or subjects sampled (e.g. age and
time differences). For example, a recent cross-sectional nation-
wide survey in Japan called the SACRA study indicated that AR was
present in 68.5% of asthmatic patients who used the self-
administered questionnaire and in 66.2% of those who received
the physician-administered questionnaire.13 Among patients with
AR, those with poly-sensitization to inhaled allergens showed a
tendency to have concomitant asthma as compared to mono-
sensitized patients, and furthermore, sensitization to mites or
cats induced comorbidity of asthma in mono-sensitized patients
with AR.7,9
The presence of concomitant AR can affect the severity of
asthma in patients who have both diseases. Nasal condition is
closely associated with the severity of the self-assessed asthma
condition and with poor asthma control both in adults and chil-
dren.14,15 A birth cohort study in the United Kingdom demonstrated
that asthmatic children with AR were 2.89 fold more likely to
experience frequent attacks of wheezing, 3.44 fold more likely to
experience severe attacks of wheezing limiting speech, 10.14 fold
more likely to have to frequently visit their doctor because of
asthma, and 9 fold more likely to miss school as compared to those
without AR.16 In addition, concomitant AR leads to a delay in the
recovery of pulmonary function tests after asthma exacerbation in
children.17 On the other hand, it is still debatable whether the
presence of asthma affects the severity of AR according to the ARIA
(allergic rhinitis and its impact on asthma) guidelines.8,9Effect of allergic rhinitis on lower airway inﬂammation and function
In the past, a “seesaw” phenomenon was proposed in which
nasal symptoms were alleviated when asthma was exacerbated
and vice versa in patients with coexisting rhinitis and asthma.
However, it is currently suggested that the severity of AR and
asthma is synchronized in general, and that the onset and/or
exacerbation of AR leads to refractory asthma.18,19 For example,
35.1% of asthmatic patients suffering from JCCP showed ann allergic upper and lower airway inﬂammation.
Fig. 2. Relationship between naso-ocular symptom score (A) and QOL (B) during the peak season of cypress pollen dispersion and the amount of IL-31 production by PBMCs in
response to Cry j 1 (from Reference 3).
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sputum and cough during the pollen dispersal season, and 31.7% of
these patients showed a decrease in morning peak expiratory ﬂow
(PEF) of greater than 10% compared with the baseline values
before pollen season.18
Hypersensitivity, obstruction and/or remodeling such as
collagen deposition in the lower airways can be detected in patients
with AR without awareness or diagnosis of asthma.20,21 Nasal
provocation with allergens leads to tissue eosinophilia in bronchi
and bronchial hyper-responsiveness to methacholine in non-
asthmatic patients with AR alone.22,23 Such obstruction and
hyper-sensitivity in lower airways is even seen in patients with
recent onset of AR.24 In addition, pollen exposure causes a signiﬁ-
cant elevation of exhaled nitric oxide in pollinosis patients without
a diagnosis of asthma.25
Several explanations have been proposed as to why the pres-
ence of AR induces inﬂammation and hyper-sensitivity of lower
airways. These explanations include: 1) recruitment into lower
airways of inﬂammatory cells activated by cytokines, chemokines
and chemical mediators produced in the upper airway, 2) direct
effect of cytokines and mediators on lower airways through the
bloodstream, 3) naso-bronchial reﬂex and neurogenic inﬂamma-
tion, 4) aspiration of post-nasal drip containing inﬂammatory cells
and mediators, and 5) nasal congestion-induced mouth breathing
which causes dryness and cooling of the lower airways.23,26
Effect of allergic rhinitis on the natural course of asthma
AR is a known risk factor for the new onset of wheeze and
asthma. A survey revealed that development of new asthma was
trebled in college students with AR that were followed for over 23
years as compared to those without rhinitis, and that this trend was
more evident in those with perennial rhinitis.27 Another longitu-
dinal population-based survey showed that the 8.8-year cumula-
tive incidence of asthma was 3.53 times higher in adult patients
with AR as compared to healthy controls.28 A similar risk is seen in
pediatric AR. AR at the age of 7 years was associated with a sig-
niﬁcant increased risk of incident asthma in preadolescence,
adolescence or adult life.29 A birth cohort study in German children
born in 1999 showed that AR up to the age of 5 years was a pre-
dictive factor for the development of wheezing between the ages of
5 and 13 years with an adjusted relative risk of 3.82.30Effect of intervention for allergic rhinitis on the natural course of
asthma
As mentioned above, the onset of AR often precedes asthma
both in children and in adults. It has therefore been investigated
whether early intervention for AR can modify the natural course of
asthma.
Allergen immunotherapy
Allergen immunotherapy is a curative treatment for AR which
can induce remission without onset of IgE-mediated nasal
symptoms.31e33 This treatment can modify the natural course of
allergic diseases, the so-called “prevention effect”, which includes
the prevention of new sensitization, of new onset of other allergic
diseases and of relapse after termination of treatment.34e37 For
example, a prospective open-labeled trial that investigated the
long-term preventive effect of a 3-year course of subcutaneous
immunotherapy (SCIT) in children with grass and/or pollen allergy
showed that SCIT-treated children had signiﬁcantly less asthma 7
years after termination of SCIT with an odds ratio of 2.5.36 A
placebo-controlled randomized 3-year study of sublingual immu-
notherapy (SLIT) with parietaria pollen vaccine for patients with AR
demonstrated that SLIT showed a tendency to suppress the devel-
opment of new onset of asthma as compared with the placebo
treatment.37
Pharmacotherapy
Pharmacotherapy for AR includes chemical mediator receptor
antagonists such as antihistamines, anti-leukotrienes and anti-
prostaglandin D2/thromboxane A2, chemical mediator release in-
hibitors such as disodium cromoglycate, Th2 cytokine inhibitors
such as suplatast tosilate, and corticosteroids.38 Among these
therapies, anti-leukotrienes have an indication for both AR and
asthma.38e40 A phase IV study demonstrated that montelukast is
effective for both upper and lower airway symptoms in adult pa-
tients suffering from both asthma and AR.41 A similar effect was
seen for intranasal corticosteroids and cromoglycate.42,43
One randomized double-blind placebo-controlled study
demonstrated that 18-months cetirizine treatment of pediatric
patients with atopic dermatitis at the age of 1e2 years suppressed
the new onset of asthma during the 18 months after termination of
the pharmacotherapy, when the children were sensitized to mites
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therapy for AR can modify the natural course of asthma. Initial (in
other words, prophylactic or early interventional) treatment with
antihistamines, anti-leukotrienes or intranasal corticosteroids
before the start of continuous pollen dispersion is known to be
effective for JCCP.38,45e47 Recently, Sagara et al. showed that initial
treatment with pranlukast plus mequitazine signiﬁcantly sup-
pressed exacerbation airway hyper-responsiveness during the
pollen season in non-asthmatic patients with JCCP.48
Surgery
Surgery is one of the treatment options for severe cases of AR
especially for those who suffer from oral breathing and/or intrac-
table watery rhinorrhea.38 Surgery includes degeneration surgery
such as laser surgery, corrective surgery of the nasal cavity such as
submucosal turbinectomy, and neurectomy of parasympathetic
nerves such as posterior nerve neurectomy.49 In patients with
rhinitis concomitant with asthma, turbinate surgery improves not
only the nasal symptoms but also asthma control.50,51 For example,
argon plasma coagulation turbinectomy reduced the prevalence of
patients with insufﬁcient asthma control, as measured by the
Asthma Control Test, from 79 to 4%, and this decrease was associ-
ated with diminished frequency of high nasal eosinophilia.51
However, to the best of our knowledge, there are no reports with
high levels of evidence that support the possibility that nasal sur-
gery might suppress the new onset of asthma in patients with AR.
Chronic rhinosinusitis and asthma
Pathological similarities and differences between chronic
rhinosinusitis and asthma
CRS is one of the most common diseases.52,53 For example in the
United States, the prevalence of CRS is 14%, and approximately
200,000 endoscopic sinus surgeries (ESS) for CRS are performed per
year.52 CRS contains a variety of phenotypes and endotypes
including CRS without nasal polyposis (CRSsNP), CRS with nasal
polyposis (CRSwNP), fungal rhinosinusitis and odontogenic CRS.54
Among these types, ECRS is histologically characterized by
massive inﬁltration of eosinophils in the lamina propria, a thick
basement membrane thickness, increased goblet cells, and
epithelial shedding in sinonasal mucosa such as nasal polyps.55
Similar immunological imbalances such as imbalances in cyto-
kines and prostaglandins are seen in both ECRS and asthma
(Fig. 3).56e60 Other molecules such as periostin appear to act as
biomarkers that reﬂect the severity of both ECRS and asthma.61,62
Thus, ECRS can be regarded as “asthma of the upper airway”.1
ECRS is the major endotype of CRSwNP in the United States andFig. 3. Inverse relationship between PGD2 synthase (h-PGDS) and PGE2 syntEurope, and has been increasing in Asia.63,64 For example, therewas
a shift from predominantly neutrophilic to eosinophilic CRSwNP in
Thai patients from 1999 to 2011.63
Presence and characterization of comorbidity of chronic
rhinosinusitis and asthma
It is well-known that CRS and asthma co-exist with a relation-
ship similar to that between AR and asthma. In general, asthma
occurs in 20e50% of patients with CRS. For example, a recent study
showed that 23.1% of patients with CRS in Japan suffered from
asthma.65 Conversely, higher incidence of radiological abnormal-
ities in paranasal sinuses was also seen in asthmatic patients.66e68
An early study showed that patients with mild-to-moderate
asthma had an 88% incidence of abnormal sinus computed to-
mography (CT) ﬁndings, while patients with severe steroid-
dependent asthma showed 100% abnormal sinus ﬁndings on CT-
scans.66 A later study also showed that increasing severity of
asthma is associated with advancing radiological severity of CRS
and a greater prevalence of allergic sensitization and nasal polyp-
osis. However, a contradictory ﬁnding was also reported.67,68
Asthmatic patients with CRS showed a signiﬁcant exacerbation of
both generic and disease-speciﬁc QOL, and had signiﬁcantly lower
percentages of predicted forced expiratory volume in 1 s and per-
centage of predicted forced vital capacity than those without CRS.69
In addition, poor outcome following ESS in CRS patients with
concomitant asthma was shown in several studies.70,71
Effect of chronic rhinosinusitis on lower airway inﬂammation and
function
Lower airway inﬂammation and dysfunction has been seen in
non-asthmatic patients with CRS. Approximately half of patients
with CRS without the diagnosis of asthma showed a marked
elevation in exhaled nitric oxide (>30 ppb).72 Similarly, approxi-
mately 70% of patients with CRS without the diagnosis of asthma
showed a bronchial hyperresponsiveness (BHR) tomethacoline.73 A
later study demonstrated that sneezing and a serum eosinophil
count of over 300 cells per microliter may be predictive factors for
BHR in patients with CRSwNP.74 We compared pulmonary function
between CRS patients without any diagnosed lung diseases and
healthy subjects. There were no signiﬁcant differences between the
two groups in terms of forced expiratory volume in 1 s and the
percentage of predicted vital capacity. However, the following pa-
rameters of pulmonary function were signiﬁcantly affected in the
CRS patients (compared with normal controls): percentage of
predicted forced expiratory volume in 1 s; forced expiratory vol-
ume in 1 s/forced vital capacity ratio; PEF; mean forced expiratoryhase (m-PGES-1) mRNA levels in sinonasal tissues (from Reference 56).
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maximal expiratory ﬂow rate at 50 per cent of vital capacity;
maximal expiratory ﬂow rate at 25 per cent of vital capacity; and
maximal expiratory ﬂow rate at 50 per cent of vital capacity/
maximal expiratory ﬂow rate at 25 per cent of vital capacity ratio
(Fig. 4). In addition, the levels of IL-5 in nasal secretion in the
middle meatus were signiﬁcantly correlated with lung function
changes.75 We have also demonstrated in another study that
obstructive lung dysfunction was more impaired in non-asthmatic
patients with CRSwNP with peripheral blood eosinophilia (eosin-
ophil percentage to total leukocyte equal or more than 5%) than in
those without eosinophilia, especially in elderly patients aged 60
years old or more.76
Similar explanations as those put forward to account for the
relationship between AR and asthma have been proposed to
explain why the presence of CRS induces lower airway inﬂamma-
tion and dysfunction.23,26 In particular, leukotrienes and cytokines
produced in inﬂamed sinonasal mucosa seem to play a major role
since urinary leukotriene excretion was signiﬁcantly decreased
after ESS.77Effect of intervention for chronic rhinosinusitis on asthma
Treatments for CRS differ among phenotypes.78 In CRSsNP,
pharmacotherapy including intranasal steroids (INS), mucolytic
agents and/or long-term antibiotics such as 14-ringmacrolides, and
local manipulation such as nasal saline irrigation are ﬁrst-line
treatment options.53,79 For example, long-term combination ther-
apy with S-carboxymethylcysteine and clarythromycin is effective
for signiﬁcantly improving subjective symptoms such as nasal
discharge and post-nasal drip and objective ﬁndings such as CT
scores in adult patients with CRS.79 On the other hand, in CRSwNP
especially ECRS, treatments that target the suppression of eosino-
phil activation and survival are considered as the ﬁrst-line. These
treatments include glucocorticoids (INS as a controller and sys-
temic steroids as a reliever), anti-leukotrienes, anti-prostaglandin
D2/thromboxane A2 and Th2 cytokine inhibitor.53,80,81 Since envi-
ronmental microbes such as Staphylococcus aureus and fungi can
evoke eosinophilia-associated cellular responses in sinonasal mu-
cosa in patients with CRSwNP, nasal saline irrigation is also rec-
ommended.58,82,83 In terms of antibiotics, doxycycline showed a
substantial effect on ECRS including on polyp size and ECP levels in
nasal secretions whereas the effect of 14-ringmacrolides on ECRS isFig. 4. Pulmonary function in patients with CRS and healthy controls. A: percentage of predi
of vital capacity.poor.81,84 Since bioﬁlm is also known to be an intractable factor in
the pathogenesis of CRS, the efﬁcacy and safety of topical anti-
bioﬁlm agents such as surfactants and manuka honey have also
been investigated.85,86 When the response to conservative treat-
ments is poor, surgery for sinus ventilation and drainage is
considered.
Pharmacotherapy
A few studies have demonstrated the efﬁcacy of pharmaco-
therapy for CRS on lower airway symptoms and functions in CRS
patients with asthma. Anti-leukotrienes show an anti-eosinophilic
inﬂammatory effect in both upper and lower airways.39,87,88 A
single-blinded, randomized, placebo-controlled trial demonstrated
that, as compared with placebo, treatment with montelukast
signiﬁcantly improved nasal symptoms and inﬂammation such as
eosinophilia in nasal smears as well as pulmonary symptoms and
PEF in patients with CRSwNP concomitant with asthma.89 On the
other hand, little is known regarding whether INS is effective for
lower airway inﬂammation and function in CRS patients. An open
trial reported that symptoms and pulmonary function signiﬁcantly
improved after treatment with a combination of amoxicillin/clav-
ulanate and ﬂuticasone propionate aqueous nasal spray in poorly-
controlled asthmatic children with CRS aged 5e12 years.90 How-
ever, a short course of oral corticosteroidwas also prescribed in that
study.
The use of biologic agents such and anti-IgE and anti-IL-5 is a
new strategy for the treatment of refractory CRS.91 Of these agents,
treatment with omalizumab, a humanized anti-IgE monoclonal
antibody, signiﬁcantly improved both upper and lower airway
pathophysiologies including nasal polyp size, radiological severity
of CRS, nasal and asthma symptoms and QOL in patients with
CRSwNP and asthma.92 Similar improvements were seen in those
who are refractory to ESS (Fig. 5).
Surgery
In contrast to pharmacotherapy, the impact of sinus surgery on
asthma has been demonstrated in a large number of studies. An
earlier study showed an improvement in PEF 6 months after ESS
ranging from 40 to 190 L/min in patients with CRS, especially ECRS,
and with asthma.93 A later study conﬁrmed the effect, and found
that medication for asthma could be reduced after surgery.70 A
more recent report showed an additional improvement in the use
of bronchodilators, oral steroids and the need for hospitalization forcted forced expiratory volume in 1 s, and B: maximal expiratory ﬂow rate at 50 percent
Fig. 5. Effect of omalizumab on refractory ECRS.
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sinus surgery improved asthma conditions. As mentioned above,
urinary levels of LTE4 were signiﬁcantly higher in asthmatic pa-
tients, and the levels were signiﬁcantly reduced following ESS.77
This ﬁnding clearly suggests that sinus tissue may be a main or-
gan for the production of LTs, and that control of upper airways
including control by ESS provides a substantial beneﬁt for asthma
control. Reduced exhaled nitric oxide is also seen in asthmatic
patients with CRS after ESS.95,96 In general, outcomes of CRS after
treatment with ESS are worse in asthmatic patients as compared to
non-asthmatics; however, based on the above information, ESS can
be a treatment option for suppression of the severity of asthma.Other treatments
Medical options other than the treatments described above
include nasal decongestants in heavily congested CRS, antimycotics
in fungal CRS, antireﬂux agents in gastro-esophageal reﬂux-asso-
ciated CRS, and aspirin desensitization in aspirin-exacerbated res-
piratory disease (AERD)-associated CRS.77,97 Of these treatments, a
beneﬁcial effect of aspirin desensitization on both upper and lower
airway symptoms has been noted in patients with AERD.97
Recently, such an efﬁcacy was conﬁrmed in a randomized,
double-blind, placebo-controlled study.98 This study clearly
demonstrated that 6 months oral aspirin desensitization after
aspirin challenge leads to signiﬁcant improvement in smell, re-
ductions in sneezing and nasal congestion, improvement of asthma
control, increase in peak nasal inspiratory ﬂows, and reduction in
the dosages of inhaled corticosteroids only in patients with aspirin-
induced asthma but not in patients with aspirin-tolerant asthma.
On the other hand, aspirin desensitization requires close moni-
toring for bronchospasm and dyspepsia.97,98Conclusions
The upper airways, especially the nose, act as a gatekeeper to
control the physiology and pathology of the lower airways. In
particular, AR and ECRS display a substantial impact on the symp-
toms and pulmonary function of asthma. Therefore, control of the
united airway inﬂammation is crucial for improving the QOL of
patients with co-existing AR/CRS and asthma. On the other hand,
except for allergen immunotherapy for AR, little is known regarding
whether early intervention for upper airway inﬂammation pre-
vents the new onset of asthma. In addition, although some in-
vestigations suggest potent candidate genes that are associated
with eosinophilic inﬂammation in both upper and lower airways,
future investigations aimed at the detection of molecules that arecritical for the induction of eosinophilic united airway inﬂamma-
tion are warranted.99,100
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